What is the Next Generation in Joint Health that addresses not only the symptoms but the causes? Reparagen® Pro.
Reparagen Pro represents a revolutionary new approach to joint health. It’s the first supplement to work at a genetic level to target the three main areas of joint function: a healthy inflammatory response2,4, the body’s normal breakdown of cartilage11 and its ability to rebuild and replace it7,8. It combines three different ingredients – Vincaria®, RNI 249® and Progrado® – and two separate clinical trials3,9 to address these three main areas of joint health and maintenance.
A New Approach to Joint Health
Reparagen Pro consists of three patented, all natural extracts: Vincaria®, RNI 249® and Progrado®. Each regulates different forms of gene expression specific to joint health. Vincaria has been shown to affect NFkB, the main “on-off switch” for a healthy inflammatory response; RNI 249 causes human cells to produce IGF-1, the master regulator for rebuilding cartilage; and, Progrado has been shown to attenuate the activity of MMPs, the molecular “scissors” that are responsible for the body’s normal breakdown of cartilage.
9 out of ten participants in a clinical trial taking a single 100mg dose of Vincaria a day experienced significant improvement in joint health. Reparagen Pro contains three times this effective dose3 93% of participants in a clinical trial taking the Vincaria-RNI 249 combination (aka Reparagen) had considerable increases in both mobility and flexibility9 In a study with Case Western Reserve University, Progrado stopped the breakdown of cartilage cells.11
Clinically validated, Reparagen Pro combines the best of nature with the power of science to promote and maximize proper and healthy joint function.
2 Aliment Pharmacol Ther 1998; 12: 1279±1289.
3 Inflammation Res, 2001, 50:442–448
4 Free Rad Bio Medicine, 2000, 29(1):71–78
5 N Eng J Med, 2006, 354:795-808
6 2007 Gallup Study of Joint Health and Glucosamine
7 Inflammation Research 54: Supplement 2, pp 115, 2005
8 BMC Complementary and Alternative Medicine 2006, 6:13
9 BMC Complementary and Alternative Medicine 2007, 7:34
10 US NIH Grant No 1R43AG024733-01
11 Journal of Translational Medicine 2008, 6:3